<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-135218" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Upadacitinib</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Padda</surname>
            <given-names>Inderbir S.</given-names>
          </name>
          <aff>Richmond University Medical Center/Mount Sinai</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Bhatt</surname>
            <given-names>Rajat</given-names>
          </name>
          <aff>Mahatma Gandhi Mission&#x02019;s Medical College</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Preeti</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Parmar</surname>
            <given-names>Mayur</given-names>
          </name>
          <aff>Nova Southeastern University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Inderbir Padda declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Rajat Bhatt declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Mayur Parmar declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>8</day>
          <month>6</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-135218.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">This&#x000a0;activity offers an in-depth examination of upadacitinib, a second-generation selective Janus kinase (JAK) inhibitor targeting the JAK1 enzyme, approved by the FDA for treating various chronic inflammatory conditions such as moderate to severe rheumatoid arthritis (RA), psoriatic arthritis, atopic dermatitis, ankylosing spondylitis, Crohn disease, and ulcerative colitis. The session will cover the specific mechanism by which upadacitinib inhibits key intracellular cytoplasmic enzymes (Janus kinases) involved in immune-mediated inflammatory diseases, disrupting the JAK-STAT signaling pathway and thereby reducing inflammatory responses.</p>
        <p>This educational initiative is designed to update healthcare professionals on the critical aspects of upadacitinib, including its adverse event profile and other essential considerations for patient management. The program will provide comprehensive insights into clinical strategies for integrating upadacitinib into treatment regimes, focusing on dosage optimization and adverse reaction mitigation to enhance patient care outcomes. By the end of this discussion, participants will be equipped with the necessary evidence-based knowledge to effectively administer upadacitinib in clinical settings.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of upadacitinib.</p></list-item><list-item><p>Evaluate the potential adverse effects of upadacitinib.</p></list-item><list-item><p>Determine&#x000a0;the appropriate monitoring for patients receiving upadacitinib.</p></list-item><list-item><p>Implement effective collaboration and communication among interprofessional team members to improve outcomes and treatment efficacy for patients who might benefit from upadacitinib therapy.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=135218&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=135218">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-135218.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Upadacitinib is a new FDA-approved second-line agent for treating moderate to severe active rheumatoid arthritis (RA) in patients who have not shown an adequate response or intolerance to the first-line agent, methotrexate.<xref ref-type="bibr" rid="article-135218.r1">[1]</xref>&#x000a0;This agent is a second-generation selective Janus kinase (JAK) inhibitor targeting the JAK1 enzyme.<xref ref-type="bibr" rid="article-135218.r2">[2]</xref> Upadacitinib received FDA approval on August 16, 2019, based on positive and promising results from its multinational phase III trials in subjects with moderate to severe rheumatoid arthritis.<xref ref-type="bibr" rid="article-135218.r3">[3]</xref></p>
        <p>Using upadacitinib with other JAK inhibitors (JAKinibs) or robust immunosuppressants like azathioprine and cyclosporine is not advised. However, its use in combination with nonbiologic disease-modifying antirheumatic drugs (DMARDs) such as methotrexate is supported, while its use with biological DMARDs is not recommended (see <bold>Image.</bold>&#x000a0;Jak Inhibitors&#x000a0;Table).<xref ref-type="bibr" rid="article-135218.r3">[3]</xref> When combined with the first-line therapy methotrexate, upadacitinib repressed disease progression on radiographic imaging and maintained clinical efficacy.<xref ref-type="bibr" rid="article-135218.r1">[1]</xref></p>
        <p>Clinical advancements for agents used in other autoimmune diseases, such as psoriatic arthritis (PA), atopic dermatitis (AD), ankylosing spondylitis (AS), giant cell arteritis (GCA), systemic lupus erythematosus (SLE), and inflammatory bowel disease (IBD), Crohn disease (CD) and ulcerative colitis (UC), have shown promising results.<xref ref-type="bibr" rid="article-135218.r3">[3]</xref> Upadacitinib marks a significant milestone as the first oral medication approved by the FDA to treat moderate to severe Crohn disease.</p>
        <p>The American Academy of Dermatology (AAD) endorses using upadacitinib for adults with moderate to severe atopic dermatitis (AD). Upadacitinib is FDA-approved for patients with AD who have failed other systemic therapies, including biologics, or when the use of those therapies is inadvisable.<xref ref-type="bibr" rid="article-135218.r4">[4]</xref> For patients with ulcerative colitis (UC) who experience recurrent pouchitis after ileal pouch-anal anastomosis (IPAA), the American Gastroenterological Association (AGA) suggests advanced immunosuppressive therapies like upadacitinib. Upadacitinib can be considered for chronic antibiotic-dependent pouchitis. Endoscopic evaluation is advised to confirm inflammation and rule out other causes. For patients with ulcerative colitis (UC) who have undergone IPAA and develop symptoms due to cuffitis, the AGA suggests using topical therapies approved for UC treatment, such as topical mesalamine and topical corticosteroids. Upadacitinib or other immunosuppressive therapies may be considered for refractory cases.<xref ref-type="bibr" rid="article-135218.r5">[5]</xref> According to the American College of Rheumatology guidelines, targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs), including JAK inhibitors like tofacitinib, baricitinib, and upadacitinib, are recommended as part of a treat-to-target (TTT) approach. This approach is strongly&#x000a0;recommended over&#x000a0;standard care for patients without prior treatment with biologic DMARDs (bDMARDs) or tsDMARDs. This recommendation extends to optimizing methotrexate dosage and subsequently adding DMARDs as needed. Although the evidence is of low certainty, this recommendation is&#x000a0;maintained due to the recognized importance of systematic monitoring and treatment adjustment to minimize inflammation, thereby preventing joint damage and other long-term complications such as cardiovascular disease and osteoporosis. In DMARD-naive patients with moderate-to-high disease activity, methotrexate monotherapy is recommended.<xref ref-type="bibr" rid="article-135218.r6">[6]</xref>&#x000a0;The&#x000a0;indication algorithm for rheumatoid arthritis is provided in&#x000a0;<bold>Image.</bold> Upadacitinib&#x000a0;for&#x000a0;Rheumatoid Arthritis&#x000a0;Algorithm.<xref ref-type="bibr" rid="article-135218.r7">[7]</xref></p>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p>The FDA has approved upadacitinib to treat several autoimmune and inflammatory conditions. The approved indications include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Rheumatoid arthritis (moderate to severe)</p>
          </list-item>
          <list-item>
            <p>Psoriatic arthritis</p>
          </list-item>
          <list-item>
            <p>Atopic dermatitis (for patients older than 12 years)&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Ankylosing spondylitis&#x000a0;<xref ref-type="bibr" rid="article-135218.r8">[8]</xref></p>
          </list-item>
          <list-item>
            <p>Crohn's disease (moderate to severe)&#x000a0;<xref ref-type="bibr" rid="article-135218.r9">[9]</xref></p>
          </list-item>
          <list-item>
            <p>Ulcerative colitis (moderate to severe)&#x000a0;<xref ref-type="bibr" rid="article-135218.r10">[10]</xref><xref ref-type="bibr" rid="article-135218.r11">[11]</xref></p>
          </list-item>
          <list-item>
            <p>Non-radiographic axial spondyloarthritis (active inflammation with inadequate response or intolerance to TNF blockers)&#x000a0;<xref ref-type="bibr" rid="article-135218.r12">[12]</xref></p>
          </list-item>
        </list>
        <p>This list reflects the range of conditions for which upadacitinib can be prescribed, highlighting its utility in treating various inflammatory disorders.</p>
      </sec>
      <sec id="article-135218.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Upadacitinib exerts its mechanism of action by inhibiting intracellular cytoplasmic enzymes Janus kinases (JAK), a group of&#x000a0;4 tyrosine kinases (JAK1, JAK2, JAK3, and TYK2) involved in the process of immune-mediated inflammatory diseases (IMIDs).<xref ref-type="bibr" rid="article-135218.r13">[13]</xref> The inhibition of JAKs further hinders growth factor and cytokine-mediated signals from being transduced intracellularly by the JAK-STAT pathway.<xref ref-type="bibr" rid="article-135218.r13">[13]</xref></p>
        <p>JAKs function by phosphorylating signal transducers and activators of transcription (STATs), regulating gene expression, and influencing hematopoiesis and immune cell function.<xref ref-type="bibr" rid="article-135218.r13">[13]</xref> Upadacitinib prevents the phosphorylation and intracellular activation of STATs, further decreasing their inflammatory effects.<xref ref-type="bibr" rid="article-135218.r14">[14]</xref> Upadacitinib has a selective and more prominent inhibitory influence on JAK1 relative to the JAK2, JAK3, and TYK2 subtypes.<xref ref-type="bibr" rid="article-135218.r15">[15]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:</bold> Following oral administration of the extended-release formulation of upadacitinib, absorption occurs within 2 to 4 hours.&#x000a0;</p>
        <p><bold>Distribution:</bold> Upadacitinib exhibits approximately 52% plasma protein binding.</p>
        <p><bold>Metabolism:</bold> Metabolism of upadacitinib primarily occurs through CYP3A4, with a minor contribution from CYP2D6.<xref ref-type="bibr" rid="article-135218.r16">[16]</xref><xref ref-type="bibr" rid="article-135218.r17">[17]</xref></p>
        <p><bold>Excretion:</bold>&#x000a0;Upadacitinib is excreted unchanged in&#x000a0;feces (38%) and urine (24%). The mean terminal elimination half-life of upadacitinib ranges from 8 to 14 hours.</p>
      </sec>
      <sec id="article-135218.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms and Strengths</bold>
</p>
        <p>Upadacitinib is available as 15 mg and 30 mg extended-release (ER) tablets for oral consumption.</p>
        <p>Before initiating treatment with upadacitinib, it is necessary to ensure that immunizations are up-to-date and to assess for active or latent tuberculosis (TB). Additional evaluations include liver function, viral hepatitis panel, and pregnancy status in females of childbearing age. Concomitant&#x000a0;administration of upadacitinib with other JAK inhibitors, biologic DMARD agents, or potent immunosuppressants such as azathioprine and cyclosporine is not recommended.</p>
        <p>
<bold>Adult Dosage</bold>
</p>
        <p>
<bold>Rheumatoid Arthritis</bold>
</p>
        <p>The recommended daily dosage is 15 mg orally as monotherapy.<xref ref-type="bibr" rid="article-135218.r3">[3]</xref> The medication may be taken with or without food and should be consumed as a whole tablet without splitting or crushing it.</p>
        <p>
<bold>Psoriatic Arthritis</bold>
</p>
        <p>The recommended daily dosage is 15 mg orally as monotherapy. The medication can be taken with or without food and&#x000a0;should be consumed as a whole tablet without splitting or crushing it.</p>
        <p>
<bold>Atopic Dermatitis</bold>
</p>
        <p>For pediatric patients aged 12 years and older and weighing&#x000a0;at least 40 kg, the recommended daily dosage is 15 mg once a day. If the therapeutic response is not reached, the dose can be increased to 30 mg daily. If the desired therapeutic response is not&#x000a0;achieved with 30 mg daily, upadacitinib should be discontinued.</p>
        <p>The recommended daily dosage for adult patients&#x000a0;younger than 65 is 15 mg once daily. If the desired therapeutic response is not achieved, the dosage can be increased to 30 mg daily. If the desired therapeutic response is not attained with 30 mg daily, upadacitinib should be discontinued.</p>
        <p>
<bold>Ulcerative Colitis</bold>
</p>
        <p>The&#x000a0;recommended initial dose of upadacitinib for induction therapy is 45 mg once daily for 8 weeks (induction phase). For maintenance therapy, the recommended dosage is 15 mg once daily. In cases of severe, refractory, or extensive ulcerative colitis, a dosage of 30 mg once daily may be considered. If an adequate therapeutic response is not attained with the 30 mg dose, upadacitinib should be discontinued. Using the lowest effective dosage required to sustain the desired response is advised.</p>
        <p>
<bold>Crohn Disease</bold>
</p>
        <p>Providers&#x000a0;should initiate treatment with upadacitinib at a dosage of 45 mg once daily for 12 weeks (induction phase).&#x000a0;For maintenance therapy, a daily dosage of 15 mg of upadacitinib is recommended. However, physicians may consider increasing the dosage&#x000a0;to 30 mg once daily for patients with severe,&#x000a0;refractory, or extensive disease. If patients do not achieve an adequate therapeutic response to the 30 mg dose, discontinuation of upadacitinib is advised. Physicians should&#x000a0;administer the lowest effective dosage necessary to maintain the desired treatment response.</p>
        <p>
<bold>Ankylosing Spondylitis</bold>
</p>
        <p>The suggested dosage of upadacitinib is 15 mg once daily.</p>
        <p>
<bold>Non-radiographic Axial Spondyloarthritis</bold>
</p>
        <p>The suggested dosage of upadacitinib is 15 mg once daily.</p>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Hepatic impairment:</bold>&#x000a0;Upadacitinib is not recommended&#x000a0;for severe hepatic impairment. For psoriatic arthritis, atopic dermatitis, rheumatoid&#x000a0;arthritis, non-radiographic axial spondyloarthritis, and ankylosing&#x000a0;spondylitis, no&#x000a0;dosage adjustment of upadacitinib is required for mild or moderate hepatic impairment (Child-Pugh A or B).&#x000a0;Patients with mild to moderate hepatic impairment require dose reduction in ulcerative colitis and Crohn disease.&#x000a0;In ulcerative colitis, the recommended regimen includes an induction dose of 30 mg once daily&#x000a0;for&#x000a0;8&#x000a0;weeks and&#x000a0;a maintenance dose of&#x000a0;15 mg once daily.&#x000a0;Similarly, patients with Crohn disease should be initiated with an induction dose of 30 mg&#x000a0;once daily for 12 weeks, followed by a maintenance&#x000a0;dose of 15 mg once daily.</p>
        <p><bold>Renal impairment:</bold>&#x000a0;</p>
        <p>For patients diagnosed with rheumatoid arthritis, psoriatic arthritis, or non-radiographic axial spondyloarthritis and ankylosing spondylitis, dosage adjustment is unnecessary&#x000a0;for mild&#x000a0;(eGFR &#x02265;60 to &#x0003c;90 mL/min/1.73 m&#x000b2;),&#x000a0;moderate (eGFR &#x02265;30 to &#x0003c;60 mL/min/1.73 m&#x000b2;), or severe renal impairment (eGFR &#x02265;15 to &#x0003c;30 mL/min/1.73 m&#x000b2;).&#x000a0;Upadacitinib has not been investigated&#x000a0;for any condition in&#x000a0;patients with&#x000a0;end-stage renal disease (eGFR &#x0003c;15 mL/min/1.73 m<sup>2</sup>).&#x000a0;</p>
        <p>For patients with&#x000a0;atopic dermatitis, the maximum recommended dosage for patients with severe renal impairment is 15 mg once daily. No dosage adjustment is necessary for&#x000a0;patients with mild or moderate renal impairment.</p>
        <p>For patients with ulcerative colitis or Crohn disease, the suggested dosage for severe renal impairment is 30 mg once daily for induction, followed by 15 mg once daily for maintenance.&#x000a0;No dosage adjustment of upadacitinib is needed for patients with mild or moderate renal impairment.&#x000a0;</p>
        <p><bold>Pregnancy considerations:</bold>&#x000a0;Upadacitinib was found to be teratogenic in animal studies, although no studies on human pregnancy have been reported.&#x000a0;Administration of upadacitinib during pregnancy is not recommended. Contraception use is advised during treatment and for 4 weeks post-treatment with upadacitinib.</p>
        <p><bold>Breastfeeding considerations:</bold>&#x000a0;Upadacitinib was also present in breast milk during animal studies, and&#x000a0;women are advised not to breastfeed while&#x000a0;receiving&#x000a0;therapy.&#x000a0;Clinicians should advise against breastfeeding while&#x000a0;administering upadacitinib. Alternative medications should be considered, particularly for preterm infants. According to the&#x000a0;product labeling&#x000a0;information, breastfeeding should be avoided for&#x000a0;6 days after the last dose of upadacitinib.<xref ref-type="bibr" rid="article-135218.r18">[18]</xref></p>
        <p><bold>Pediatric patients:</bold>&#x000a0;For pediatric patients&#x000a0;with atopic dermatitis aged 12 years and older and weighing at least 40 kg, the recommended starting dose of upadacitinib is 15 mg once daily. If the desired response is not attained, the dosage of upadacitinib may be increased to 30 mg once daily. Upadacitinib should be discontinued if the 30 mg dose is ineffective. The lowest effective dose required to sustain the desired response should be used.</p>
        <p><bold>Older patients</bold>: The suggested dosage of&#x000a0;upadacitinib is&#x000a0;15 mg once daily for older patients with atopic dermatitis.&#x000a0;In older&#x000a0;adults (65 years and older)&#x000a0;with various conditions, including ulcerative colitis, Crohn disease, ankylosing spondylitis, rheumatoid arthritis, psoriatic arthritis, atopic dermatitis,&#x000a0;and non-radiographic axial spondyloarthritis, no difference in effectiveness was observed compared to younger patients. However, older patients&#x000a0;are at an&#x000a0;increased risk of&#x000a0;general adverse events, including infection and&#x000a0;malignancy.</p>
      </sec>
      <sec id="article-135218.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Upadacitinib has various adverse effects, which are listed below.<xref ref-type="bibr" rid="article-135218.r19">[19]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Upper respiratory tract infections (URTI) (14%)</p>
          </list-item>
          <list-item>
            <p>Nausea (4%)</p>
          </list-item>
          <list-item>
            <p>Elevated liver enzymes (2%)</p>
          </list-item>
          <list-item>
            <p>Fever (1%)</p>
          </list-item>
          <list-item>
            <p>Cough (2%)</p>
          </list-item>
        </list>
        <p>Upper respiratory tract infections (URTI) encompass:</p>
        <list list-type="bullet">
          <list-item>
            <p>Acute sinusitis</p>
          </list-item>
          <list-item>
            <p>Laryngitis</p>
          </list-item>
          <list-item>
            <p>Nasopharyngitis</p>
          </list-item>
          <list-item>
            <p>Oropharyngeal pain</p>
          </list-item>
          <list-item>
            <p>Pharyngitis</p>
          </list-item>
          <list-item>
            <p>Pharyngotonsillitis</p>
          </list-item>
          <list-item>
            <p>Rhinitis</p>
          </list-item>
          <list-item>
            <p>Sinusitis</p>
          </list-item>
          <list-item>
            <p>Tonsillitis</p>
          </list-item>
          <list-item>
            <p>Viral upper respiratory tract infection</p>
          </list-item>
        </list>
        <p>These adverse effects were observed during placebo-controlled studies where subjects were administered 15 mg of oral upadacitinib.<xref ref-type="bibr" rid="article-135218.r3">[3]</xref> More severe adverse effects, such as herpes zoster virus (HZV) and serious infections, were seen in subjects administered 30 mg in a double-blind, randomized, controlled phase 3 clinical trial (&#x0003c;1%).<xref ref-type="bibr" rid="article-135218.r19">[19]</xref> Clinical studies have also reported malignancy, thrombosis, and gastrointestinal (GI) perforations with concomitant non-steroidal anti-inflammatory drugs (NSAIDs) use.<xref ref-type="bibr" rid="article-135218.r3">[3]</xref> Headache, acne, upper respiratory tract infection, and elevated creatine phosphokinase (CPK) levels were common adverse events observed in adolescents receiving upadacitinib for atopic dermatitis.<xref ref-type="bibr" rid="article-135218.r20">[20]</xref> In a study investigating the adverse effects associated with upadacitinib, data from the Food and Drug Administration Adverse Event Reporting System (FAERS) spanning from 2004 to 2023 were analyzed. The study reported adverse drug reactions (ADRs), including vulvar dysplasia, acne, mediastinal neoplasm, eczema herpeticum, lip neoplasm, herpes zoster, eosinopenia, ureteral neoplasm, and <italic toggle="yes">Moraxella</italic> infection.<xref ref-type="bibr" rid="article-135218.r21">[21]</xref></p>
        <p><bold>Drug-Drug Interactions:&#x000a0;</bold>Upadacitinib is metabolized in the liver by the cytochrome P450 (CYP) system, primarily through the CYP3A4 enzyme, and is eliminated in the feces and urine as metabolites, with a drug half-life of 8 to 14 hours. The concomitant use of CYP3A4 inhibitors and CYP3A4 inducers should be approached with caution and is generally not recommended, as it may alter the drug's pharmacokinetics, potentially increasing or decreasing drug plasma concentrations. Clinical studies have also reported malignancy, thrombosis, and gastrointestinal (GI) perforations with concomitant use of non-steroidal anti-inflammatory drugs (NSAIDs).<xref ref-type="bibr" rid="article-135218.r3">[3]</xref><xref ref-type="bibr" rid="article-135218.r19">[19]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Upadacitinib exposure may increase when used concurrently with strong CYP3A4 inhibitors such as grapefruit, ketoconazole, and clarithromycin, potentially exacerbating the risk of adverse reactions. Patients should avoid consuming grapefruit or grapefruit-containing products during upadacitinib treatment.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>For patients with atopic dermatitis or Crohn disease who are prescribed strong CYP3A4 inhibitors, the induction dosage of upadacitinib should be reduced to 30 mg once daily while maintaining the maintenance dosage at 15 mg once daily. Conversely, strong CYP3A4 inducers such as rifampin may decrease upadacitinib exposure, potentially diminishing its therapeutic effects. Therefore, co-administration of upadacitinib with strong CYP3A4 inducers is not advised.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-135218.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>The use of upadacitinib with biological DMARDs (infliximab, adalimumab, etanercept, abatacept, tofacitinib) and immunosuppressants (azathioprine, tacrolimus, cyclosporine, intravenous (IV) corticosteroids, and 6-mercaptopurine) is not recommended.<xref ref-type="bibr" rid="article-135218.r22">[22]</xref> Administration of a live attenuated vaccine shortly before or during treatment is also not advised.<xref ref-type="bibr" rid="article-135218.r23">[23]</xref></p>
        <p>
<bold>US Boxed Warning:</bold>
</p>
        <p>Infections, malignancy, thrombosis, tuberculosis, death, and major adverse cardiovascular events (MACE) are significant risks.<xref ref-type="bibr" rid="article-135218.r24">[24]</xref></p>
        <p>Recent updates in upadacitinib use have shown an increased rate of all-cause mortality and sudden cardiovascular-associated mortality when used concurrently with another JAK inhibitor agent versus tumor necrosis factor (TNF) inhibitors in subjects with RA. MACE includes cardiovascular mortality, myocardial infarction (MI), and stroke.</p>
        <p>
<bold>Warnings and Precautions:</bold>
</p>
        <p>Patients taking upadacitinib may notice medication residue in their stool or ostomy output, especially in cases involving a colostomy, ileostomy, intestinal resection, or shortened transit times. If patients observe repeated instances of medication residue, they should promptly notify their healthcare provider. Clinical monitoring is recommended, and alternative treatment options should be considered if there is an inadequate therapeutic response. The predominant serious infections associated with upadacitinib include pneumonia, cellulitis, tuberculosis, herpes zoster, oral and esophageal candidiasis, and cryptococcosis.<xref ref-type="bibr" rid="article-135218.r25">[25]</xref><xref ref-type="bibr" rid="article-135218.r26">[26]</xref> The product labeling notes an increased frequency of serious infections with the higher 30 mg dosage of upadacitinib compared to the 15 mg dosage.</p>
      </sec>
      <sec id="article-135218.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Before initiating treatment with upadacitinib, a negative tuberculosis (TB) test is required as it may reactivate latent TB infection. During treatment with upadacitinib, patients should be routinely tested for TB. A complete blood count (CBC) must be monitored before starting therapy and routinely after that; initiating upadacitinib is not recommended for subjects with an absolute lymphocyte count (ALC) below 500 cells/mm&#x000b3; or an absolute neutrophil count (ANC) below 1,000 cells/mm&#x000b3;. Reports of lymphopenia, neutropenia, and anemia exist. Liver function tests (LFTs) should be checked before beginning therapy and regularly after that, as patients with severe hepatic impairment are not advised to start treatment.<xref ref-type="bibr" rid="article-135218.r27">[27]</xref>&#x000a0;The lipid panel should also be monitored 12 weeks after starting treatment, as increases in total cholesterol, low-density lipoprotein (LDL) cholesterol, and high-density lipoprotein (HDL) cholesterol may occur.</p>
        <p>Patients should be monitored for serious infections during therapy, as severe bacterial, viral, fungal, tuberculous, and opportunistic infections have occurred, leading to hospitalization and mortality in patients receiving upadacitinib. In such cases, the treatment regime must be interrupted and halted. Monitoring for reactivation of prior hepatitis B virus (HBV) or herpes zoster virus (HZV) infections is recommended, as these infections were reported during clinical studies. Upadacitinib should be temporarily discontinued until HZV is resolved.<xref ref-type="bibr" rid="article-135218.r3">[3]</xref></p>
        <p>Subjects at increased risk for skin cancers receiving treatment are advised to undergo routine skin examinations, as they have an increased risk of non-melanoma skin cancers (NMSCs). Patients receiving upadacitinib with concomitant NSAID use should be monitored for new-onset gastrointestinal manifestations, as GI perforations have been reported during clinical studies.</p>
      </sec>
      <sec id="article-135218.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Upadacitinib was found to be teratogenic in animal studies, although no human studies during pregnancy have been reported. Use during pregnancy is not recommended. Contraception is advised during treatment and for 4 weeks after completing treatment with upadacitinib.</p>
        <p>
<bold>Hepatotoxicity</bold>
</p>
        <p>The pattern of liver injury associated with upadacitinib indicates a potential for low-level, direct hepatotoxicity. During the initial weeks of treatment, ALT levels may slightly increase, typically returning to baseline upon discontinuation of the drug. Serum aminotransferase elevations above 5 times the upper limit of normal should prompt consideration of dose reduction or temporary cessation of upadacitinib treatment. Managing potential hepatotoxicity carefully is essential for minimizing further liver injury. Close monitoring of liver function tests is crucial during this period to ensure timely intervention and appropriate management.<xref ref-type="bibr" rid="article-135218.r17">[17]</xref></p>
        <p>There is no information regarding overdose of upadacitinib in the FDA-approved product labeling.</p>
      </sec>
      <sec id="article-135218.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Upadacitinib is a second-generation selective Janus kinase inhibitor targeting the JAK1 enzyme. This medication is FDA-approved to treat active moderate to severe rheumatoid arthritis in patients who are intolerant or unresponsive to first-line therapy with methotrexate (MTX). Managing rheumatoid arthritis requires decisive care from an interprofessional team of healthcare professionals. Early clinical analysis and diagnosis can lead to more effective management strategies, decreasing lifelong complications and improving the quality of life. The interprofessional team can include physicians, nurse practitioners, physician assistants, rheumatologists, nurses, a physical therapist (PT), and a pharmacist. For severe atopic dermatitis, consultation with a dermatologist may be required. Consultation with a gastroenterologist is necessary when using upadacitinib for inflammatory bowel disease. A phase 3 clinical trial, comprising 2 induction trials, U-EXCEL and U-EXCEED, and one maintenance trial, U-ENDURE, was conducted across 43 countries at 277 sites. U-EXCEL and U-EXCEED involved a 12-week double-blind, placebo-controlled induction treatment period, demonstrating the efficacy of upadacitinib in treating moderate-to-severe Crohn disease.<xref ref-type="bibr" rid="article-135218.r28">[28]</xref></p>
        <p>Rheumatologists and primary care physicians (PCPs) should maintain continuous communication regarding their patient's care and updates on the latest treatment guidelines. Patients should be thoroughly educated about rheumatoid arthritis, therapy with upadacitinib, and its potential adverse effects. The interdisciplinary team should monitor the patient's CBC, liver enzymes, and lipid panel before initiating treatment and routinely after that. Particular attention should be paid to the lymphocyte count, absolute neutrophil count, and hemoglobin (Hgb), as lymphopenia, neutropenia, and anemia may occur during therapy. Treatment should be avoided or halted if the patient's absolute lymphocyte count is below 500 cells/mm&#x000b3;, the absolute neutrophil count is below 1,000 cells/mm&#x000b3;, or the Hgb level is below 8 g/dL.</p>
        <p>The primary care physician&#x000a0;must monitor total cholesterol, low-density lipoprotein (LDL) cholesterol, and high-density lipoprotein (HDL) cholesterol levels 12 weeks after treatment initiation, given the possibility of elevated levels, which may require prompt management. Every patient initiating treatment should have TB screening with a tuberculin skin test (TST) or interferon-&#x003b3; release assay (IGRA). Patients with a positive TB test should be treated before starting treatment with upadacitinib.</p>
        <p>Patients should be advised about the broad range of adverse effects while on therapy. Routine follow-ups with the PCP and specialist are essential to prevent complications, hospitalization, and mortality. New-onset gastrointestinal symptoms must be thoroughly evaluated, as GI perforation has been reported in clinical studies, particularly with concomitant NSAID use. Patients should also be counseled about the increased risk of severe infections, and any new-onset clinical manifestation should be reported and investigated.</p>
        <p>In reproductive animal studies, upadacitinib was shown to cause injury to the developing fetus and be present in breast milk. During pregnancy, women should be advised and counseled about upadacitinib use and the likely effects on the fetus and to discontinue breastfeeding while on therapy. Women should also be counseled on contraception use while being treated and for 4 weeks after discontinuation of treatment. Intercommunication between the healthcare team and their patients is imperative to establish a solid physician-patient relationship. This can further increase medication compliance and decrease disease progression, improving the quality of life. An interprofessional team approach and open communication between clinicians (MDs, DOs, NPs, PAs), pharmacists, rheumatologists, gastroenterologists, and dermatologists are necessary to optimize patient outcomes with upadacitinib therapy.</p>
      </sec>
      <sec id="article-135218.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=135218&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=135218">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/135218/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=135218">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-135218.s11">
        <fig id="article-135218.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Upadacitinib for Rheumatoid Arthritis Algorithm Contributed by I Padda, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Upadacitinib__For__RA" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-135218.s12">
        <fig id="article-135218.image.f2" position="float" orientation="portrait">
          <caption>
            <p>Jak Inhibitors Table Contributed by I Padda, MD; Updated by Preeti Patel, PharmD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Jak__Inhibitor__Table" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-135218.s13">
        <title>References</title>
        <ref id="article-135218.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Serhal</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Edwards</surname>
                <given-names>CJ</given-names>
              </name>
            </person-group>
            <article-title>Upadacitinib for the treatment of rheumatoid arthritis.</article-title>
            <source>Expert Rev Clin Immunol</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>15</volume>
            <issue>1</issue>
            <fpage>13</fpage>
            <page-range>13-25</page-range>
            <pub-id pub-id-type="pmid">30394138</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135218.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tanaka</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>A review of upadacitinib in rheumatoid arthritis.</article-title>
            <source>Mod Rheumatol</source>
            <year>2020</year>
            <month>Sep</month>
            <volume>30</volume>
            <issue>5</issue>
            <fpage>779</fpage>
            <page-range>779-787</page-range>
            <pub-id pub-id-type="pmid">32530345</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135218.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Duggan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Keam</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>Upadacitinib: First Approval.</article-title>
            <source>Drugs</source>
            <year>2019</year>
            <month>Nov</month>
            <volume>79</volume>
            <issue>16</issue>
            <fpage>1819</fpage>
            <page-range>1819-1828</page-range>
            <pub-id pub-id-type="pmid">31642025</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135218.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Davis</surname>
                <given-names>DMR</given-names>
              </name>
              <name>
                <surname>Drucker</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Alikhan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bercovitch</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Darr</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Eichenfield</surname>
                <given-names>LF</given-names>
              </name>
              <name>
                <surname>Frazer-Green</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Paller</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Schwarzenberger</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Silverberg</surname>
                <given-names>JI</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Sidbury</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2024</year>
            <month>Feb</month>
            <volume>90</volume>
            <issue>2</issue>
            <fpage>e43</fpage>
            <page-range>e43-e56</page-range>
            <pub-id pub-id-type="pmid">37943240</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135218.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barnes</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Agrawal</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Syal</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ananthakrishnan</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Haydek</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Al Kazzi</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Eisenstein</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hashash</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Sultan</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Raffals</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>S</given-names>
              </name>
              <collab>AGA Clinical Guidelines Committee. Electronic address: clinicalpractice@gastro.org</collab>
            </person-group>
            <article-title>AGA Clinical Practice Guideline on the Management of Pouchitis and Inflammatory Pouch Disorders.</article-title>
            <source>Gastroenterology</source>
            <year>2024</year>
            <month>Jan</month>
            <volume>166</volume>
            <issue>1</issue>
            <fpage>59</fpage>
            <page-range>59-85</page-range>
            <pub-id pub-id-type="pmid">38128971</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135218.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fraenkel</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bathon</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>England</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>St Clair</surname>
                <given-names>EW</given-names>
              </name>
              <name>
                <surname>Arayssi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Carandang</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Deane</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Genovese</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Huston</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Kerr</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kremer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Nakamura</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Russell</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Sparks</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Venkatachalam</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Weinblatt</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Al-Gibbawi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Baker</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Barbour</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Barton</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Cappelli</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Chamseddine</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>George</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Kahale</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Karam</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Khamis</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Navarro-Mill&#x000e1;n</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Mirza</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Schwab</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Turgunbaev</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Turner</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Yaacoub</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Akl</surname>
                <given-names>EA</given-names>
              </name>
            </person-group>
            <article-title>2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.</article-title>
            <source>Arthritis Care Res (Hoboken)</source>
            <year>2021</year>
            <month>Jul</month>
            <volume>73</volume>
            <issue>7</issue>
            <fpage>924</fpage>
            <page-range>924-939</page-range>
            <pub-id pub-id-type="pmid">34101387</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135218.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smolen</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Landew&#x000e9;</surname>
                <given-names>RBM</given-names>
              </name>
              <name>
                <surname>Bijlsma</surname>
                <given-names>JWJ</given-names>
              </name>
              <name>
                <surname>Burmester</surname>
                <given-names>GR</given-names>
              </name>
              <name>
                <surname>Dougados</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kerschbaumer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>McInnes</surname>
                <given-names>IB</given-names>
              </name>
              <name>
                <surname>Sepriano</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>van Vollenhoven</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>de Wit</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Aletaha</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Aringer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Askling</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Balsa</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Boers</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>den Broeder</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Buch</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Buttgereit</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Caporali</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cardiel</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>De Cock</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Codreanu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cutolo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Edwards</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>van Eijk-Hustings</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Emery</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Finckh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gossec</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Gottenberg</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Hetland</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Huizinga</surname>
                <given-names>TWJ</given-names>
              </name>
              <name>
                <surname>Koloumas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Mariette</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>M&#x000fc;ller-Ladner</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Mysler</surname>
                <given-names>EF</given-names>
              </name>
              <name>
                <surname>da Silva</surname>
                <given-names>JAP</given-names>
              </name>
              <name>
                <surname>Po&#x000f3;r</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Pope</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Rubbert-Roth</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ruyssen-Witrand</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Saag</surname>
                <given-names>KG</given-names>
              </name>
              <name>
                <surname>Strangfeld</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Takeuchi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Voshaar</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Westhovens</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>van der Heijde</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update.</article-title>
            <source>Ann Rheum Dis</source>
            <year>2020</year>
            <month>Jun</month>
            <volume>79</volume>
            <issue>6</issue>
            <fpage>685</fpage>
            <page-range>685-699</page-range>
            <pub-id pub-id-type="pmid">31969328</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135218.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Raychaudhuri</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Banerjee</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Raychaudhuri</surname>
                <given-names>SK</given-names>
              </name>
            </person-group>
            <article-title>JAK-STAT Signaling and Beyond in the Pathogenesis of Spondyloarthritis and Their Clinical Significance.</article-title>
            <source>Curr Rheumatol Rep</source>
            <year>2024</year>
            <month>Jun</month>
            <volume>26</volume>
            <issue>6</issue>
            <fpage>204</fpage>
            <page-range>204-213</page-range>
            <pub-id pub-id-type="pmid">38492148</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135218.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dignass</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Esters</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Flauaus</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Upadacitinib in Crohn's disease.</article-title>
            <source>Expert Opin Pharmacother</source>
            <year>2024</year>
            <month>Mar</month>
            <volume>25</volume>
            <issue>4</issue>
            <fpage>359</fpage>
            <page-range>359-370</page-range>
            <pub-id pub-id-type="pmid">38512115</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135218.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Irani</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fan</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Glassner</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Abraham</surname>
                <given-names>BP</given-names>
              </name>
            </person-group>
            <article-title>Clinical Evaluation of Upadacitinib in the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis (UC): Patient Selection and Reported Outcomes.</article-title>
            <source>Clin Exp Gastroenterol</source>
            <year>2023</year>
            <volume>16</volume>
            <fpage>21</fpage>
            <page-range>21-28</page-range>
            <pub-id pub-id-type="pmid">36915649</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135218.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Panaccione</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Danese</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Klaff</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ilo</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Yao</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Higgins</surname>
                <given-names>PDR</given-names>
              </name>
              <name>
                <surname>Loftus</surname>
                <given-names>EV</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gonzalez</surname>
                <given-names>YS</given-names>
              </name>
              <name>
                <surname>Leonard</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>H&#x000e9;buterne</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Lindsay</surname>
                <given-names>JO</given-names>
              </name>
              <name>
                <surname>Cao</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Nakase</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Colombel</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Vermeire</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and safety of upadacitinib for 16-week extended induction and 52-week maintenance therapy in patients with moderately to severely active ulcerative colitis.</article-title>
            <source>Aliment Pharmacol Ther</source>
            <year>2024</year>
            <month>Feb</month>
            <volume>59</volume>
            <issue>3</issue>
            <fpage>393</fpage>
            <page-range>393-408</page-range>
            <pub-id pub-id-type="pmid">38010661</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135218.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Harrison</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Marzo-Ortega</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Have Therapeutics Enhanced Our Knowledge of Axial Spondyloarthritis?</article-title>
            <source>Curr Rheumatol Rep</source>
            <year>2023</year>
            <month>Mar</month>
            <volume>25</volume>
            <issue>3</issue>
            <fpage>56</fpage>
            <page-range>56-67</page-range>
            <pub-id pub-id-type="pmid">36652160</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135218.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kotyla</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Islam</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Engelmann</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Clinical Aspects of Janus Kinase (JAK) Inhibitors in the Cardiovascular System in Patients with Rheumatoid Arthritis.</article-title>
            <source>Int J Mol Sci</source>
            <year>2020</year>
            <month>Oct</month>
            <day>07</day>
            <volume>21</volume>
            <issue>19</issue>
            <pub-id pub-id-type="pmid">33036382</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135218.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baker</surname>
                <given-names>KF</given-names>
              </name>
              <name>
                <surname>Isaacs</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis?</article-title>
            <source>Ann Rheum Dis</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>77</volume>
            <issue>2</issue>
            <fpage>175</fpage>
            <page-range>175-187</page-range>
            <pub-id pub-id-type="pmid">28765121</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135218.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lin</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Cooles</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Isaacs</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Basic Mechanisms of JAK Inhibition.</article-title>
            <source>Mediterr J Rheumatol</source>
            <year>2020</year>
            <month>Jun</month>
            <volume>31</volume>
            <issue>Suppl 1</issue>
            <fpage>100</fpage>
            <page-range>100-104</page-range>
            <pub-id pub-id-type="pmid">32676567</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135218.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mohamed</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Minocha</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Trueman</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Feng</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Enejosa</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fisniku</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Othman</surname>
                <given-names>AA</given-names>
              </name>
            </person-group>
            <article-title>Characterization of the Effect of Upadacitinib on the Pharmacokinetics of Bupropion, a Sensitive Cytochrome P450 2B6 Probe Substrate.</article-title>
            <source>Clin Pharmacol Drug Dev</source>
            <year>2021</year>
            <month>Mar</month>
            <volume>10</volume>
            <issue>3</issue>
            <fpage>299</fpage>
            <page-range>299-306</page-range>
            <pub-id pub-id-type="pmid">32648334</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135218.r17">
          <label>17</label>
          <element-citation publication-type="book">
            <chapter-title>Upadacitinib</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2022</year>
            <month>8</month>
            <day>30</day>
            <pub-id pub-id-type="pmid">34633781</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135218.r18">
          <label>18</label>
          <element-citation publication-type="book">
            <chapter-title>Upadacitinib</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2021</year>
            <month>1</month>
            <day>18</day>
            <pub-id pub-id-type="pmid">32816423</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135218.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Genovese</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Fleischmann</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Combe</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Hall</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rubbert-Roth</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Mohamed</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Meerwein</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pangan</surname>
                <given-names>AL</given-names>
              </name>
            </person-group>
            <article-title>Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial.</article-title>
            <source>Lancet</source>
            <year>2018</year>
            <month>Jun</month>
            <day>23</day>
            <volume>391</volume>
            <issue>10139</issue>
            <fpage>2513</fpage>
            <page-range>2513-2524</page-range>
            <pub-id pub-id-type="pmid">29908670</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135218.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Paller</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Ladizinski</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Mendes-Bastos</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Siegfried</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Soong</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Prajapati</surname>
                <given-names>VH</given-names>
              </name>
              <name>
                <surname>Lio</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Thyssen</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Simpson</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Platt</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Raymundo</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Calimlim</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Gu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Su</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Zheng</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yamamoto-Hanada</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Teixeira</surname>
                <given-names>HD</given-names>
              </name>
              <name>
                <surname>Irvine</surname>
                <given-names>AD</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and Safety of Upadacitinib Treatment in Adolescents With Moderate-to-Severe Atopic Dermatitis: Analysis of the Measure Up 1, Measure Up 2, and AD Up Randomized Clinical Trials.</article-title>
            <source>JAMA Dermatol</source>
            <year>2023</year>
            <month>May</month>
            <day>01</day>
            <volume>159</volume>
            <issue>5</issue>
            <fpage>526</fpage>
            <page-range>526-535</page-range>
            <pub-id pub-id-type="pmid">37043227</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135218.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Wei</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>A real-world pharmacovigilance analysis of FDA adverse event reporting system database for upadacitinib.</article-title>
            <source>Front Pharmacol</source>
            <year>2023</year>
            <volume>14</volume>
            <fpage>1200254</fpage>
            <pub-id pub-id-type="pmid">37663269</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135218.r22">
          <label>22</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Benjamin</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Goyal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lappin</surname>
                <given-names>SL</given-names>
              </name>
            </person-group>
            <chapter-title>Disease-Modifying Antirheumatic Drugs (DMARD)</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>7</month>
            <day>3</day>
            <pub-id pub-id-type="pmid">29939640</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135218.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sandborn</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Ghosh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Panes</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Schreiber</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>D'Haens</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Tanida</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Siffledeen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Enejosa</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Othman</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Higgins</surname>
                <given-names>PDR</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of Upadacitinib in a Randomized Trial of Patients With Active Ulcerative Colitis.</article-title>
            <source>Gastroenterology</source>
            <year>2020</year>
            <month>Jun</month>
            <volume>158</volume>
            <issue>8</issue>
            <fpage>2139</fpage>
            <page-range>2139-2149.e14</page-range>
            <pub-id pub-id-type="pmid">32092309</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135218.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Charles-Schoeman</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Choy</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>McInnes</surname>
                <given-names>IB</given-names>
              </name>
              <name>
                <surname>Mysler</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Nash</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Yamaoka</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lippe</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Shmagel</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Palac</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Suboticki</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Curtis</surname>
                <given-names>JR</given-names>
              </name>
            </person-group>
            <article-title>MACE and VTE across upadacitinib clinical trial programmes in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.</article-title>
            <source>RMD Open</source>
            <year>2023</year>
            <month>Nov</month>
            <volume>9</volume>
            <issue>4</issue>
            <pub-id pub-id-type="pmid">37945286</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135218.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wolfenbarger</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Britt</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>A Case of Pulmonary Cryptococcosis Caused by Capsule-Deficient Cryptococcus neoformans.</article-title>
            <source>Cureus</source>
            <year>2023</year>
            <month>Nov</month>
            <volume>15</volume>
            <issue>11</issue>
            <fpage>e48196</fpage>
            <pub-id pub-id-type="pmid">38054144</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135218.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Valor-M&#x000e9;ndez</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Manger</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Wacker</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kleyer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Schett</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Lymph node and pulmonary tuberculosis during upadacitinib treatment in a psoriatic arthritis patient.</article-title>
            <source>Rheumatol Adv Pract</source>
            <year>2022</year>
            <volume>6</volume>
            <issue>2</issue>
            <fpage>rkac032</fpage>
            <pub-id pub-id-type="pmid">35601270</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135218.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Trueman</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mohamed</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Feng</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Lacerda</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Marbury</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Othman</surname>
                <given-names>AA</given-names>
              </name>
            </person-group>
            <article-title>Characterization of the Effect of Hepatic Impairment on Upadacitinib Pharmacokinetics.</article-title>
            <source>J Clin Pharmacol</source>
            <year>2019</year>
            <month>Sep</month>
            <volume>59</volume>
            <issue>9</issue>
            <fpage>1188</fpage>
            <page-range>1188-1194</page-range>
            <pub-id pub-id-type="pmid">30973649</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135218.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Loftus</surname>
                <given-names>EV</given-names>
              </name>
              <name>
                <surname>Pan&#x000e9;s</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lacerda</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Peyrin-Biroulet</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>D'Haens</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Panaccione</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Reinisch</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Louis</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nakase</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Begun</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Boland</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Phillips</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mohamed</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Geng</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Feng</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Dubcenco</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Colombel</surname>
                <given-names>JF</given-names>
              </name>
            </person-group>
            <article-title>Upadacitinib Induction and Maintenance Therapy for Crohn's Disease.</article-title>
            <source>N Engl J Med</source>
            <year>2023</year>
            <month>May</month>
            <day>25</day>
            <volume>388</volume>
            <issue>21</issue>
            <fpage>1966</fpage>
            <page-range>1966-1980</page-range>
            <pub-id pub-id-type="pmid">37224198</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
